Drug Index



Mechanism :

The mode of action of sulfasalazine or its metabolites, 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP), is still under investigation, but may be related to the anti-inflammatory and/or immunomodulatory properties and to its affinity for connective tissue, and/or to the relatively high concentration it reaches in serous fluids, the liver and intestinal walls.

Indication :

• Inflammatory bowel disease

• Juvenile idiopathic arthritis

Contraindications :

Hypersensitivity to sulfasalazine, its metabolites, sulfonamides or salicylate in patients with intestinal or urinary obstruction and in patients with porphyria, as the sulfonamides have been reported to precipitate an acute attack. Contraindicated in children <2 years of age and caution in patients with G6PD deficiency.

Dosing :

<2 years: Safety and efficacy not established.

≥2 years: Acute Attack or relapse: 40-60 mg/kg/day PO in divided doses, Maintenance Dosage: 20-30 mg/kg/day PO in divided doses.

Adverse Effect :

Cyanosis, hemolytic anemia, stomatitis, elevated hepatic enzymes, leukopenia, thrombocytopenia, hypoglycemia, goitre, nausea, anorexia, vomiting, oligospermia, headache, dyspepsia, rash, abdominal pain, fever, pruritus, dizziness, urticaria, exacerbation of colitis

Interaction :

Digoxin and Folic Acid: May reduce gastrointestinal absorption.
Antibiotics: That alter intestinal flora may interfere with conversion of sulfasalazine to sulfapyridine and 5-aminosalicylic acid (5-ASA) decreasing its effectiveness.

03/05/2020 08:59:52 Sulfasalazine
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0